SCHEMBL6204508

SCHEMBL6204508

NC(=O)Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3nnn(-c4ccccc4)c3c2)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 2/20 0.41
MAPK14 Q16539 7/20 0.38
TGFBR1 P36897 1/20 0.38
TGFBR2 P37173 1/20 0.38
MAPT P10636 2/20 0.37
MAPK13 O15264 1/20 0.37
RAF1 P04049 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
MDM2 Q00987 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183189 0.90 MAPK14 (0.40) NT5EMAPK14MAPTCYP3A4LMNA
SCHEMBL6184681 0.86 NT5E (0.42) NT5EMAPK14TGFBR1TGFBR2MAPK13
SCHEMBL6186458 0.84 NT5E (0.43) NT5EMAPK14TGFBR1TGFBR2MAPK13
SCHEMBL6186115 0.83 NT5E (0.42) NT5EMAPK14TGFBR1TGFBR2MAPT
SCHEMBL6184293 0.82 NT5E (0.41) NT5EMAPK14TGFBR1TGFBR2MAPT
SCHEMBL6184613 0.77 KCNMA1 (0.43) NT5EMAPK14TGFBR1MEN1KMT2A
SCHEMBL6183056 0.76 MAPK14 (0.43) NT5EMAPK14TGFBR1ALDH1A1SMN1; SMN2
SCHEMBL6184877 0.75 IDO1 (0.60) NT5EMAPK14TGFBR1TGFBR2MAPT
SCHEMBL6185563 0.73 MAPK14 (0.43) NT5EMAPK14HPGDMEN1KMT2A
SCHEMBL6182069 0.73 NT5E (0.41) NT5EMAPK14ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1247810-B1 Novel benzotriazoles anti-inflammatory compounds PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6664395-B2 Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia PFIZER INC 2003-12-16 US disclosed
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds PFIZER INC. 2003-04-24 US disclosed
EP-1247810-A1 Novel benzotriazoles anti-inflammatory compounds Pfizer Products Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds MAPK1, JAK1, RUNX1 NT5E 4156/4885MAPK14 27/4885TGFBR1 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.